Bionano Genomics, Inc. BNGO

BNGO Company Overview

Bionano Genomics, Inc. is a U.S.-based life sciences company focused on genome analysis technologies used in cytogenetics and molecular diagnostics research. The company develops systems and software designed to detect structural variations and genome abnormalities that may be difficult to identify with traditional sequencing methods. Bionano operates primarily in the genomics and biotechnology industries, serving academic research institutions, clinical laboratories, biopharmaceutical companies, and translational medicine organizations. Its core revenue drivers include instrument sales, consumables, software subscriptions, and related services associated with its optical genome mapping platform.

The company’s primary commercial platform is the Saphyr system, which enables optical genome mapping for the detection of large-scale structural variants in DNA. Bionano also offers software and informatics tools including Bionano Access and Bionano Solve, as well as diagnostic and imaging capabilities added through acquisitions. The company traces its origins to 2003 and evolved from a genomics tools developer into a broader cytogenetics and genome analysis platform provider through internal development and acquisitions, including the acquisitions of BioDiscovery, Inc. and Lineagen, Inc. Its strategic positioning centers on providing complementary genome analysis capabilities alongside next-generation sequencing technologies.